Долгосрочное применение латанопроста в лечении глаукомы

Закрыть метаданные

Глаукома — главная причина необратимой слепоты в мире. Латанопрост, эфирное пролекарство простагландина F2α (PGF2α), был первым аналогом простагландина, применявшимся для лечения глаукомы. В обзоре показано, что латанопрост обладает наиболее сбалансированным соотношением по эффективности и безопасности по сравнению с другими аналогами простагландинов, его применение повышает качество жизни больных глаукомой, обеспечивает суточный контроль внутриглазного давления (ВГД), высокую приверженность больных лечению и сохранение ими зрительных функций в отдаленном периоде. Продемонстрирована возможность длительного (более пяти лет) применения препарата, а также эффективное комплексное лечение с использованием латанопроста и β-блокаторов. Рассмотрены возможности использования латанопроста у детей, а также нейропротекторные свойства препарата.

Ключевые слова:

аналог простагландина F2α (PGF2α)

глаукома

прогрессирование глаукомы

24-часовой контроль внутриглазного давления

приверженность лечению

качество жизни

нейропротекция

Авторы:

Курышева Н.И.

Офтальмологический центр Федерального медико-биологического агентства, ул. Гамалеи, 15, Москва, Российская Федерация, 123098

Список литературы:

Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367-1377. https://doi.org/10.1016/S0140-6736(10)61423-7
Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013
Guidelines for Glaucoma Eye Care [PDF]. International Council of Ophthalmology. 2016. Accessed February 4, 2020. https://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf
Terminology and Guidelines for Glaucoma [internet pages]. European Glaucoma Society. 2014. Accessed February 4, 2020. http://www.eugs.org/eng/guidelines.asp
Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129-140. https://doi.org/10.1016/j.ophtha.2015.09.005
Prum BE, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern Guidelines. Ophthalmology. 2016;123(1):41-111. https://doi.org/10.1016/j.ophtha.2015.10.053
Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13(5):723-745. https://doi.org/10.1517/14656566.2012.662219
Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropyl ester in the cynomolgus monkey. Exp Eye Research. 1989;48:707-716. https://doi.org/10.1016/0014-4835(89)90011-0
Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Investigative Ophthalmology & Visual Science. 2002;43:716-722.
Sagara T, Gaton DD, Lindsey JD, Gabelt B’AT, Kaufman PL, Weinreb RN. Topical prostaglandin F2 α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794-801. https://doi.org/10.1001/archopht.117.6.794
Konstas A, Koliakos G, Kanhardt as C, Liakos P, Schlotzer-Schrehaedt U, Ritch R. Latanoprost therapy reduces the levels of TGF beta 1 and gelatinases in the aqueous humor of patients with exfoliative glaucoma. Experimental Eye Research. 2006;82(2):319-322. https://doi.org/10.1016/j.exer.2005.07.004
Курышева Н.И. Новые возможности и перспективы использования латанопроста (Ксалатан, Pfizer, США) в лечении псевдоэксфолиативной глаукомы. Офтальмологические ведомости. 2013;6(1):61-65. https://doi.org/10.17816/ov2013161-65
Konstas A, Kozobolis V. Efficacy and safety of latanoprost versus travaprost in exfoliative glaucoma patients. Ophthalmology. 2007;114(4):653-657. https://doi.org/10.1016/j.ophtha.2006.07.064
Tam ALC, Gupta N, Zhang Z, Yücel YH. Latanoprost stimulates ocular lymphatic drainage: an in vivo nanotracer study. Translational Vision Science & Technology. 2013;2(5):3. https://doi.org/10.1167/tvst.2.5.3
Yücel YH, Johnston MG, Ly T, Patel M, Drake B, Gümüş E, et al. Identification of lymphatics in the ciliary body of the human eye: A novel «uveolymphatic» outflow pathway. Experimental Eye Research. 2009;89(5):810-819. https://doi.org/10.1016/j.exer.2009.08.010
Alm A, Stjernschantz J. Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or Morning. Ophthalmology. 1995;102(12):1743-1752. https://doi.org/10.1016/s0161-6420(95)30798-1
Короев О.А., Хадикова Э.В., Короев А.О. и др. Гипотензивный эффект местного применения ксалатана в зависимости от инволюционных изменений переднего отдела сосудистого тракта. Российский офтальмологический журнал. 2016;9(2):38-41. https://doi.org/10.21516/2072-0076-2016-9-2-38-41
Alm A, Widengard I, Kjellgren D, Soderstrom M, Fristrom B, Heijl A, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. British Journal of Ophthalmology. 1995;79(1):12-16. https://doi.org/10.1136/bjo.79.1.12
O’Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. British Journal of Ophthalmology. 2000;84(6):579-582. https://doi.org/10.1136/bjo.84.6.579
Alm A. A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive Latanoprost Therapy for Glaucoma. Archives of Ophthalmology. 2004;122(7):957. https://doi.org/10.1001/archopht.122.7.957
Курышева Н.И., Ходак Н.А., Трубилин В.Н. Исследование нейропротекторного действия Ксалатана в клинике. Глаукома. 2008;2:35-40.
Рябцева А.А., Хомякова Е.Н., Сергушев С.Г. Мониторинг гипотензивного эффекта препарата Ксалатан у больных первичной открытоугольной глаукомой в сочетании с миопией. Клиническая Офтальмология. 2008;3:110.
Kara C, Şen EM, Elgin KU, Serdar K, Yilmazbaş P. Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term? International Ophthalmology. 2016;37(3):619-626. https://doi.org/10.1007/s10792-016-0315-3
Ikeda Y, Mori K, Tada K, Ueno M, Kinoshita S, Sotozono C. Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. Clinical Ophthalmology. 2016;8(10):1633-1637. https://doi.org/10.2147/opth.s108213
Fogagnolo P, Dipinto A, Vanzulli E, Maggiolo E, De Cilla’ S, Autelitano A, et al. A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients. Advances in Therapy. 2015;32(4):356-369. https://doi.org/10.1007/s12325-015-0205-5
Birt CM, Buys YM, Ahmed II, Trope GE. Prostaglandin Efficacy and Safety Study Undertaken by Race (The PRESSURE Study). Journal of Glaucoma. 2010;19(7):460-467. https://doi.org/10.1097/ijg.0b013e3181c4aeac
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma. Ophthalmology. 2016;123(1):129-140. https://doi.org/10.1016/j.ophtha.2015.09.005
Mishra D, Sinha BP, Kumar MS. Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma. Korean Journal of Ophthalmology. 2014;28(5):399. https://doi.org/10.3341/kjo.2014.28.5.399
Lin L, Zhao YJ, Chew PTK, Sng CCA, Wong H-T, Yip LW, et al. Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy. 2014;48(12):1585-1593. https://doi.org/10.1177/1060028014548569
Chen R, Yang K, Zheng Z, Ong M-L, Wang N-L, Zhan S-Y. Meta-analysis of the Efficacy and Safety of Latanoprost Monotherapy in Patients With Angle-closure Glaucoma. Journal of Glaucoma. 2016;25(3):134-144. https://doi.org/10.1097/ijg.0000000000000158
Жукова О.В., Золотарев А.В. Эффективность латанопроста при различных формах глаукомы и внутриглазной гипертензии у детей. Русский медицинский журнал. 2014;4:10-14.
Younus M, Schachar RA, Zhang M, Sultan MB, Tressler CS, Huang K, et al. A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study. American Journal of Ophthalmology. 2018;196:101-111. https://doi.org/10.1016/j.ajo.2018.08.039
Black AC, Jones S, Yanovitch TL, Enyedi LB, Stinnett SS, Freedman SF. Latanoprost in pediatric glaucoma — pediatric exposure over a decade. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2009;13(6):558-562. https://doi.org/10.1016/j.jaapos.2009.10.003
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. The Lancet. 2015;385(9975):1295-1304. https://doi.org/10.1016/s0140-6736(14)62111-5
Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of Long-term Progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114(11):1965-1972. https://doi.org/10.1016/j.ophtha.2007.03.016
Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Böhres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study. Arch Ophthalmol. 2001;119:191-196.
Gaddie IB, Bennett DW. Cystoid macula edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69:122-128.
Hernstadt DJ, Husain R. Effect of prostaglandin analogue use on the development of cystoid macular edema after phacoemulsification using STROBE statement methodology. Journal of Cataract and Refractive. 2017;43(4):564-569. https://doi.org/10.1016/j.jcrs.2017.03.005
Selen F, Tekeli O, Yanık Ö. Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs. Journal of Ocular Pharmacology and Therapeutics. 2017;33(3):170-175. https://doi.org/10.1089/jop.2016.0128
Курышева Н.И., Полунина Е.В., Арджуханов Д.Д., Тхамодакова А.М. Влияние тафлупроста и тафлопрост/тимолола на толщину сетчатки в макулярной области. Российский офтальмологический журнал. 2019;12(1):18-24. https://doi.org/10.21516/2072-0076-2019-12-1-18-24
Kurysheva N. Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination. Taiwan Journal of Ophthalmology. 2019;9(2):93. https://doi.org/10.4103/tjo.tjo_108_17
Ge J, Li X, Sun X, et al. Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution). Zhonghua Yan Ke Za Zhi. 2015;51(2):95-102.
Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2016;254(6):1151-1158. https://doi.org/10.1007/s00417-016-3299-9
Lin L, Zhao YJ, Chew PTK, Sng CCA, Wong H-T, Yip LW, et al. Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy. 2014;48(12):1585-1593. https://doi.org/10.1177/1060028014548569
Rouland J-F, Traverso CE, Stalmans I, Fekih LE, Delval L, Renault D, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. British Journal of Ophthalmology. 2012;97(2):196-200. https://doi.org/10.1136/bjophthalmol-2012-302121
Stolz J, Alm A. Latanoprost in the treatment of glaucoma. Clinical Ophthalmology. 2014;1967-1985. https://doi.org/10.2147/opth.s59162
Quaranta L, Biagioli E, Riva I, Rulli E, Poli D, Katsanos A, et al. Prostaglandin Analogs and Timolol-Fixed Versus Unfixed Combinations or Monotherapy for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis. Journal of Ocular Pharmacology and Therapeutics. 2013;29(4):382-389. https://doi.org/10.1089/jop.2012.0186
Inoue K, Masumoto M, Higa R, Wakakura M, Kohmoto H, Kei Noguchi, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clinical Ophthalmology. 2012;771-775. https://doi.org/10.2147/opth.s31085
Palmberg P, Kim EE, Kwok KK, Tressler CS. A 12-Week, Randomized, Double-Masked Study of Fixed Combination Latanoprost/Timolol versus Latanoprost or Timolol Monotherapy. European Journal of Ophthalmology. 2010;20(4):708-718. https://doi.org/10.1177/112067211002000411
Liu AW, Gan LY, Yao X, et al. Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. International Journal of Ophthalmology. 2016;9(5):750-756. https://doi.org/10.18240/ijo.2016.05.21
Xing Y, Jiang FG, Li T. Fixed combination of latanoprost and timolol vs the individual components for primary open angle glaucoma and ocular hypertension: a systematic review and meta-analysis. International Journal of Ophthalmology. 2014;7(5):879-890.
Lou H, Wang H, Zong Y, Cheng J-W, Wei R-L. Efficacy and tolerability of prostaglandin — timolol fixed combinations: an updated systematic review and meta-analysis. Current Medical Research and Opinion. 2015;31(6):1139-1147. https://doi.org/10.1185/03007995.2015.1039504
Cheng J-W, Cheng S-W, Gao L-D, Lu G-C, Wei R-L. Intraocular Pressure-Lowering Effects of Commonly Used Fixed-Combination Drugs with Timolol: A Systematic Review and Meta-Analysis. PLoS ONE. 2012;7(9):e45079. https://doi.org/10.1371/journal.pone.0045079
Inoue K, Okayama R, Higa R, Sawada H, Wakakura M, Tomita G. Ocular Hypotensive Effects and Safety over 3 Months of Switching from an Unfixed Combination to Latanoprost 0.005%/Timolol Maleate 0.5% Fixed Combination. Journal of Ocular Pharmacology and Therapeutics. 2011;27(6):581-587. https://doi.org/10.1089/jop.2011.0057
Konstas AGP, Quaranta L, Bozkurt B, Katsanos A, Garcia-Feijoo J, Rossetti L, et al. 24-h Efficacy of Glaucoma Treatment Options. Advances in Therapy. 2016;33(4):481-517. https://doi.org/10.1007/s12325-016-0316-7
Quaranta L, Gandolfo F, Turano R, Rovida F, Pizzolante T, Musig A, et al. Effects of Topical Hypotensive Drugs on Circadian IOP, Blood Pressure, and Calculated Diastolic Ocular Perfusion Pressure in Patients with Glaucoma. Investigative Opthalmology & Visual Science. 2006;47(7):2917-2923. https://doi.org/10.1167/iovs.05-1253
Liu CJ-L, Ko Y-C, Cheng C-Y, Chou JC, Hsu W-M, Liu J-H. Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma. British Journal of Ophthalmologу. 2002;86(11):1236-1239. https://doi.org/10.1136/bjo.86.11.1236
Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmologica Scandinavica. 2007;85(8):838-843. https://doi.org/10.1111/j.1600-0420.2007.00960.x
Quaranta L, Pizzolante T, Riva I, Haidich A-B, Konstas AGP, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. British Journal of Ophthalmology. 2008;92(9):1227-1231. https://doi.org/10.1136/bjo.2008.138024
Schwartz GF, Tan J, Kotak S. Hyperemia-Associated Costs of Medication Changes in Glaucoma Patients Treated Initially With Prostaglandin Analogs. Journal of Ocular Pharmacology and Therapeutics. 2009;25(6):555-562. https://doi.org/10.1089/jop.2009.0057
Orme M, Collins S, Dakin H, Kelly S, Loftus J. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Current Medical Research and Opinion. 2009;26(3):511-528. https://doi.org/10.1185/03007990903498786
Курышева Н.И., Шаталова Е.О., Лепешкина Л.В. Прогрессирование глаукомной оптической нейропатии и его предикторы. Научно-практический журнал по офтальмологии «Восток—Запад. Точка зрения». 2018;3:7-10. https://doi.org/10.25276/2410-1257-2018-7-10
Paletta Guedes P, Guedes RAP, Freitas, Chaoubah. Quality of life of glaucoma patients under medical therapy with different prostaglandins. Clinical Ophthalmology. 2012;6:1749-1753. https://doi.org/10.2147/opth.s37347
Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Experimental Eye Research. 2011;93(3):265-270. https://doi.org/10.1016/j.exer.2011.06.022
Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Experimental Eye Research. 2009;88(3):535-541. https://doi.org/10.1016/j.exer.2008.11.012
Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost Exerts Neuroprotective Activity in vitro and in vivo. Experimental Eye Research. 2001;72(4):479-486. https://doi.org/10.1006/exer.2000.0975
McCullough L. Neuroprotective Function of the PGE2 EP2 Receptor in Cerebral Ischemia. Journal of Neuroscience. 2004;24(1):257-268. https://doi.org/10.1523/jneurosci.4485-03.2004
Odani N, Seike H, Kurashima H. Protective effect of latanoprost on glutamate-induced cytotoxicity. World Glaucoma Congress. Singapore; 2007;184-185.
Kudo H, Nakazawa T. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2007;3:15-19. https://doi.org/10.1007/s00417-005-0215-0
Kokkinaki M, Abu-Asab M, Gunawardena N, Ahern G, Javidnia M, Young J, et al. Klotho Regulates Retinal Pigment Epithelial Functions and Protects Against Oxidative Stress. Journal of Neuroscience. 2013;33(41):16346-16359. https://doi.org/10.1523/jneurosci.0402-13.2013
Yamamoto K, Sato K, Yukita M, Yasuda M, Omodaka K, Ryu M, et al. The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. Journal of Neurochemistry. 2016;140(3):495-508. https://doi.org/10.1111/jnc.13902
Курышева Н.И., Азизова О.А., Пирязев А.П. Сравнительное исследование антиоксидантной активности комбинированных препаратов для местного гипотензивного лечения глаукомы. Российский офтальмологический журнал. 2013;2(6):41-44.
Fuma S, Shimazawa M, Imamura T, Kanno Y, Takano N, Tsuruma K, et al. Neuroprotective Effect of Ocular Hypotensive Drugs: Latanoprost/Timolol in Combination Are More Effective than Each as Monotherapy in RGC-5. Biological and Pharmaceutical Bulletin. 2016;39(2):192-198. https://doi.org/10.1248/bpb.b15-00584

Закрыть метаданные